{"groups":[{"description":"Patients receive sunitinib 50 mg PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.","id":"FG000","title":"Treatment (Sunitinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never Start Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Disease Progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Eligible patients for arm-V must have a somatic cKIT mutation in exon 9, 11, 13 or 14, excluding exon 17 or 18 mutations, activating PDGFRA or PDGFRB variants and fusions, or another aberration as identified in the protocol. The mutation status was determined by an NCI-MATCH approved laboratory for 6 patients in this arm, these cases had to be confirmed to be used in primary analysis.","recruitmentDetails":"Subprotocol V was activated on August 12, 2015. A total of 10 patients were enrolled between November 1, 2016 and May 21, 2020. Four patients were enrolled on the basis of the results from the NCI-MATCH assay and 6 on the basis of the outside assay results."}